Solli Covers ixInsights 2025: What Patients Really Expect and How Pharma Can Deliver
A new study from ixlayer and Ipsos reveals a significant shift in what patients expect from pharmaceutical companies—and it has major implications for how brands design digital health and patient-engagement programs.
“Patients are seeking more support from pharma.”
— From the ixInsights report via Solli
Key findings include:
- A whopping 92% of respondents reported they have used patient portals.
- 82% of patients said they have accessed telehealth platforms.
- Despite high adoption, 50% say they must use multiple digital tools, and 27% report technical issues.
- Only 16% of respondents strongly agree that pharma companies are patient-centric today—but 81% believe pharma should help them access care and medicines.
- Patients are clear: nearly 83% say their perception of a pharma company would improve if it offered services such as virtual consultations or digital pharmacy delivery.
“It is crucial for all stakeholders to focus on integrating and developing tools that put patients at the core.” – Chareen Lim, SVP, Ipsos Healthcare.
“Patients don’t just want treatment from pharma—they want seamless, digital-first healthcare experiences that fit into their lives.” – Pouria Sanae, Co-founder & CEO, ixlayer .
What this means for pharma brands:
- Digital health is no longer optional — it’s table-stakes. With high usage among patients, brands must ensure their experiences match consumer expectations.
- Fragmentation remains a core barrier. Patients want more integrated experiences rather than disconnected tools.
- Pharma has a clear opportunity to build trust by delivering actionable digital services, not just educational ones. Brands that bridge the gap from awareness to action will lead.
- For program designers, the mandate is to move upstream in the patient journey — from diagnosis and screening through to therapy — and leverage digital health as the connective tissue.
In short: the data is loud and clear. Patients expect pharma to engage not just as drug-makers, but as partners in care. Brands that embrace this shift—and deliver digital, accessible, end-to-end experiences—will differentiate themselves, deepen patient trust, and future-proof their model.
Read the full ixInsights 2025 Research Report: https://ixlayer.com/ixinsights-research-white-paper-2025/
Read Solli’s coverage about ixlayer’s ixInsights 2025 study and patient survey results: https://solli.global/ixinsights-2025-unpacking-the-ixlayer-ipsos-report/
About ixlayer
ixlayer has the only end-to-end, direct-to-patient platform built for biopharma and optimized for patient choice. We help biopharma companies connect with patients from testing to treatment with speed, transparency, control and impact.
